ALLEXCEL
FRIDAY, October 5, 2018 14:36
prev
next
Headquarters Address
135 Wood Street, Suite 200.West Haven, CT 06516
Phone: 203-907-0237
Fax: 203-764-2037
info@allexcel.com
Our patented and proprietary nanomedicines involve: (a) development, synthesis, purification, testing, and production scale-up, of certain polymer and plastics-based materials with special emphasis on biocompatibility, biodegradability, and aspects for use as medicines, inside the body and also as external creams and lotions, (b) development, synthesis, purification, testing, and production scale-up, of certain small chemicals that serve as targeting ligands like beacons, and (c) chemically connecting the ligands in step (b) to polymers in step (a) to make the polymers intelligent so that they can then find their target specifically. In addition, for certain drugs, we also perform (d) "encapsulation" of a known active pharmaceutical ingredient (API) into the " belly" of the TheraCour micelle.
These steps result in highly potent, highly specific, therapeutics that go to the exact site, and drop the API, or release it over a period of time, as the functional requirement may be. The address of the site is encoded by the small chemical ligand, like a zip code on a mailing envelope. Such specific delivery, sparing normal host cells, tissues, and organs, and certain additional design features have allowed us to develop drugs with extremely strong safety profiles.
Further, we are now engaged in the development of (e) "encapsulation" of factory-produced cells in a viable form for protection in situ upon implantation in the patient.
We are always looking for highly skilled individuals with expertise in these and related areas.
AllExcel, Inc is a product development laboratory located in West Haven, Connecticut.
Additionally, we also perform work at a modern nanomedicines lab in Shelton, CT.The name reflects the multiple dimensions of business that we have expanded into. AllExcel is engaged in (1) R&D Chemicals and Supplies, (2) R&D Instrumentation, (3) Nanomedicine Technologies, and, most recently, (4) Regenerative Cell Therapy technologies. Our primary focus is the further development of our Nanomedicine Technologies and Platforms for therapeutics development against a wide variety of diseases.
Pioneering, Field-Defining Nanomedicines Technologies
Since 1992, AllExcel, Inc. has been an early pioneer in developing technology in the field of what are now called "nanomedicines". AllExcel has developed as yet unmatched industry leading capabilities in our platform technology that we call "TheraCour®".
TheraCour is a micelle forming, self-assembling, polymeric material that has the unique and highly sought-after capabilities:
> TheraCour can take drugs to specific cancer cells, bacterial cells or virus particles while sparing normal human cells, based on a zip-code-like address based targeting.
> TheraCour enables tailoring of the pharmaceutical lifetime of a drug, as per the requirement of the specific disease and the intervention. It is possible to achieve short term lifetime of a few hours, a medium lifetime of a couple of days, and even weeks. This enables excellent patient compliance.
> TheraCour enables tailoring for optimal drug delivery by any route, be it injectable, transdermal, topical ocular, or even oral. This minimizes the formulation stage in drug development. In contrast, liposomal drugs may require years of formulation optimization.
> TheraCour-based drug candidates have been found to be inherently safe in a multitude of studies against a wide variety of diseases.
> TheraCour-based drug candidates have demonstrated very high effectiveness in a number of animal models of different diseases.
> TheraCour enables encapsulation of therapeutic cells so that they can be manufactured, protected in the TheraCour gel, and implanted into a patient while minimizing cell death from host effects, to cure degenerative diseases such as Diabetes, Liver Disease, Cardiac Muscle, Neurodegenration, Parkinson's Disease and more.
Our Nanomedicine Technologies Are In Commercialization Phase
In 2003, Dr. Diwan won our first patent in the nanomedicines field. In 2004, TheraCour Pharma, Inc. was formed with outside investors to commercialize the patented as well as several additional patentable and patent-pending nanomedicine technologies developed at AllExcel, Inc.
In 2005, TheraCour Pharma further licensed its technologies to NanoViricides, Inc., for the development of a number of antiviral drugs. NanoViricides, Inc. became a public company through a reverse shell merger in 2005, became a SEC reporting company in 2008, and has become a NYSE American listed company in September 2013 (symbol: NNVC; website www.nanoviricides.com). NanoViricides has several drug candidates based on our technologies in its pipeline. A drug candidate to treat Shingles is currently advancing towards clinical trials, with drug candidates against HSV1 "cold sores" treatment and HSV2 "genital ulcers treatment following thereafter. Additional drugs in development at NanoViricides based on our technologies include drugs against Influenza viruses, Dengue viruses, HIV, and Ebola/Marburg, among others.
Thus the technologies developed by AllExcel, Inc. are having a significant economic impact already.
We anticipate that TheraCour Pharma will develop drugs against several cancers and many other non-viral diseases as funding becomes available to it.
AllExcel, Inc. continues to service TheraCour Pharma for the production and manufacture of the nanomedicine materials. In addition, AllExcel, Inc. is also performing independent research in a number of areas.
Pioneering Regenerative Cell Therapy Technologies Ready for Spin-off
Additionally, AllExcel scientists have developed a factory-manufacturable cell line to treat Parkinson's disease (PD). PD is caused by the death of substantia nigra cells in the brain. Our approach is to replace these cells with HLA-matched cells, like organ transplant, but factory- manufactured (unlike organ transplant) so that the patient can carry on a normal life. While several researchers are working on cell replacement approaches, their approaches are limited because of use of stem cells from certain sources and the need for retroviral vector engineering of those cells.
If successful, such implantation would cure PD. Currently there is no cure for PD, and existing therapies have significant side-effects and also become progressively ineffective. AllExcel is currently seeking investments to spin-off this technology into a separate company, as we have done in the past with TheraCour Pharma, Inc., and NanoViricides, Inc.
allexcel.com |
